Monoclonal Antibodies Market Size Worth $135.6 Billion By 2025 | CAGR: 4.8%
Published Date : 13 / 09 / 17 | Report Format: PDF
The global monoclonal antibodies market is expected to grow at growth rate of 4.8% to reach USD 135.6 billion by 2025. Antibodies and antibody fragments has become an essential tool for biomedical research and rapidly gaining popularity as therapeutic moiety globally.Constant increase inn therapeutic and diagnostic applications of mAbs is expected to contribute to the market development. In recent years, mAbs accounted for the largest share of all biologic therapies.
The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Murine segment is the lowest revenue generating segment, accounted for only 7.54% share of the global market in 2016. The adoption of murine antibodies as therapeutics is limited by their immunogenicity as the mouse antibodies are seen by human systems as a foreign particle.
In terms of diseases, the market is segmented as autoimmune diseases, inflammatory diseases, Infectious diseases and others. Cancer segment dominated the market. Avastin, Heceptin and Rituxan are the highest selling monoclonal antibody therapeutics for the treatment of cancer. However, sale of monoclonal antibodies for infectious diseases, arthritis and inflammatory diseases also growing at decent growth rate owing to the expected approval of novel mAb therapeutics in coming years. End user segment is divided as hospitals, research laboratories and others.
Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of approvals and favorable government support augment the market growth in developed region. Asia Pacific region is expected to growth at CAGR of 9.98% during the future period.
Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market.
KEY BENEFITS OF THE REPORT:
- Understanding of the strategies that are being adopted by the key players in this market to stay competitive
- Extensive analysis of the key players dominating the competitive landscape of this market
- In-depth analysis of the key factors are propelling the growth of the global market
- Detailed analysis of the geographic region that will witness the strongest growth
- Granular analysis of the current market scenario and the expected market grow
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY SOURCE
MARKET, BY DISEASE
- Autoimmune diseases
- Inflammatory diseases
- Infectious diseases
MARKET, BY END USE
- Research labs
MARKET, BY REGION
- North America
- Asia Pacific
- Rest of the World
MARKET, BY COUNTRY
- Further Breakdown of The North America Market
- Further Breakdown of The Europe Market
- Rest of Europe
- Further Breakdown of The APAC Market
- Rest of APAC
- Further Breakdown of The Rest of the World Market
- Middle East and Africa
- Latin America
We strive to become one of the trusted partner of our client by offering value added services and concrete research data.
Tailor Made Solutions
From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round our client’s exact needs.
Our analyst aims to provide research studies in quickest turnaround time and in a much cost effective manner.
Data Accuracy And Reliablity
We utilize a mix of primary, secondary research, and machine learning algorithms to generate accurate and comprehensive data about market size and revenue forecasts.
We offer most competitive pricing policy across the research industry
Why Choose Us
We devise research report with quality data:
Combined with an in-depth knowledge of the current industry and a sharp analytical mind, AnalystView serve our customer accurate research in accordance with a constantly evolving industry.
We work with businesses just like yours:
AnalystView committed to making a positive difference for our clients. This means whatever you demand, chances are we already have experience with something similar.